Skip to main navigation Skip to search Skip to main content

Advances in nanobased platforms for cardiovascular diseases: Early diagnosis, imaging, treatment, and tissue engineering

  • Laleh Shariati
  • , Yasaman Esmaeili
  • , Ilnaz Rahimmanesh
  • , Shahrzad Babolmorad
  • , Ghazal Ziaei
  • , Anwarul Hasan
  • , Maryam Boshtam*
  • , Pooyan Makvandi*
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations

Abstract

Cardiovascular diseases (CVDs) present a significant threat to health, with traditional therapeutics based treatment being hindered by inefficiencies, limited biological effects, and resistance to conventional drug. Addressing these challenges requires advanced approaches for early disease diagnosis and therapy. Nanotechnology and nanomedicine have emerged as promising avenues for personalized CVD diagnosis and treatment through theranostic agents. Nanoparticles serve as nanodevices or nanocarriers, efficiently transporting drugs to injury sites. These nanocarriers offer the potential for precise drug and gene delivery, overcoming issues like bioavailability and solubility. By attaching specific target molecules to nanoparticle surfaces, controlled drug release to targeted areas becomes feasible. In the field of cardiology, nanoplatforms have gained popularity due to their attributes, such as passive or active targeting of cardiac tissues, enhanced sensitivity and specificity, and easy penetration into heart and artery tissues due to their small size. However, concerns persist about the immunogenicity and cytotoxicity of nanomaterials, necessitating careful consideration. Nanoparticles also hold promise for CVD diagnosis and imaging, enabling straightforward diagnostic procedures and real-time tracking during therapy. Nanotechnology has revolutionized cardiovascular imaging, yielding multimodal and multifunctional vehicles that outperform traditional methods. The paper provides an overview of nanomaterial delivery routes, targeting techniques, and recent advances in treating, diagnosing, and engineering tissues for CVDs. It also discusses the future potential of nanomaterials in CVDs, including theranostics, aiming to enhance cardiovascular treatment in clinical practice. Ultimately, refining nanocarriers and delivery methods has the potential to enhance treatment effectiveness, minimize side effects, and improve patients' well-being and outcomes.

Original languageEnglish
Article number116933
JournalEnvironmental Research
Volume238
DOIs
StatePublished - 1 Dec 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cardiac tissue engineering
  • Cardiovascular diseases
  • Diagnosis
  • Nanotechnology
  • Nanotheranostics

ASJC Scopus subject areas

  • Biochemistry
  • General Environmental Science

Fingerprint

Dive into the research topics of 'Advances in nanobased platforms for cardiovascular diseases: Early diagnosis, imaging, treatment, and tissue engineering'. Together they form a unique fingerprint.

Cite this